Biogen, Elan report Phase III Antegren data

BIIB and ELN released one-year data from the two-year Phase III AFFIRM trial of Antegren natalizumab to treat relapsing-remitting multiple sclerosis (RRMS) in which the compound met the primary endpoint of a significant decrease in relapse rates compared with placebo. Antegren patients showed a 66% reduction in relapse rate versus placebo. The antibody against integrin alpha (4) also met secondary endpoints of the number of new or newly enlarging T2-hyperintense lesions, the number of gadolinium-enhancing lesions and the proportion of patents who were relapse free. ...